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A B S T R A C T
Patients with uncontrolled hypertension are at risk for cardiovascular complications. The majority of them
suffers from unidentified forms of hypertension and a fraction has so-called secondary hypertension with an
identifiable cause. The patient’s medications, its use of certain herbal supplements and over-the-counter agents
represent potential causal factors for secondary hypertension that are often overlooked. The current review
focuses on drugs that are likely to elevate blood pressure by affecting the human endocrine system at the level of
steroid synthesis or metabolism, mineralocorticoid receptor activity, or by affecting the catecholaminergic
system. Drugs with known adverse effects but where benefits outweigh their risks, drug candidates and market
withdrawals are reviewed. Finally, potential therapeutic strategies are discussed.
1. Introduction
The majority of diagnosed hypertensive patients suffer from idio-
pathic hypertension. Secondary forms of hypertension due to an iden-
tifiable cause are less prevalent and found in approximately 10% of
adult hypertensive patients and in up to 30% of patients with treat-
ment-resistant hypertension [1–4]. However, a recent review described
primary aldosteronism (PA) as a major public health problem, with
inappropriate aldosterone secretion detected in up to 50% of patients
with essential hypertension [5]. Other causes of secondary hyperten-
sion include obstructive sleep apnea (prevalence> 15%), renal par-
enchymal disease (1–8%), renal artery stenosis (1–8%), Cushing’s
syndrome (CS) (< 0.1%), hyper-/hypothyroidism (<1%), pheochro-
mocytoma (0.2-0.6%), and coarctation of the aorta (0.1%) [1,4,6].
Concomitant medications promoting hypertension or blunting the ef-
fects of anti-hypertensive therapy are frequently underrecognized by
health care providers as contributors to secondary hypertension [7,8].
The patient’s personal use of certain herbal supplements, over-the-
counter agents or psychostimulants associated with blood pressure
elevation renders individual assessments even more demanding. Im-
portantly, a direct relationship between the degree of vascular disease
and mortality risk over the normal range of blood pressure has been
demonstrated [9]. Moreover, even a reduction of as little as 2mm Hg of
systolic blood pressure has been shown to lower mortality due to stroke
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by 10% and due to ischemic heart disease by 7% [9]. This raises the
question whether a slight increase of blood pressure, although still in
the “normal” range, represents an unappreciated clinical issue. There-
fore, it is crucial to consider the patient’s medications as potential
contributors to blood pressure elevation and to know the underlying
pathways in order to apply an appropriate therapy. Three major me-
chanisms leading to blood pressure elevation can be distinguished:
plasma volume expansion, increased sympathetic activity and direct
vasoconstriction [10]. This review outlines mechanisms of drug-in-
duced blood pressure elevation due to direct interference with the en-
docrine system, including the mimicking of endogenous hormones or
disturbance of hormone synthesis, transport and metabolism.
2. Mineralocorticoid effects
2.1. Interference with adrenal steroidogenesis
The central role of the adrenal glands in stress responses makes
them a particularly sensitive organ as seen in toxicological studies [11].
Despite this, the assessment of off-target effects on the adrenals in en-
docrine-related drug toxicity studies represents a neglected topic of
investigation, although administration of drugs such as etomidate and
aminoglutethimide caused the death of patients due to unrecognized
interference with adrenocortical steroidogenesis [12]. The importance
of evaluating drug candidates for their potential to interfere with
steroidogenic enzymes has recently been addressed by the United States
Food and Drug Administration guidance on non-clinical evaluation of
endocrine-related drug toxicity [13]. It recommends the use of cyto-
chrome P450 (CYP) isoenzyme assays during early drug development,
including those for CYP11A1, CYP11B1, CYP11B2, CYP17A1 and
CYP21A1 that are involved in adrenal androgen, mineralo- and gluco-
corticoid synthesis.
CYP11B1 (also known as 11β-hydroxylase) catalyzes the conversion
of 11-deoxycortisol to the potent glucocorticoid cortisol, whereas
CYP11B2 (also known as aldosterone synthase) converts 11-deox-
ycorticosterone (11-DOC) via corticosterone and 18-hydro-
xycorticosterone to the potent mineralocorticoid aldosterone [14]. In-
hibition of CYP11B1 results in decreased cortisol production along with
increased levels of 11-deoxycortisol and 11-DOC that possess miner-
alocorticoid activity and can result in low renin levels. Diminished
CYP11B2 activity leads to decreased aldosterone production and ac-
cumulation of its substrate 11-DOC [15,16]. In the human circulation
only about 6% of 11-DOC is not bound to plasma proteins,
whereas> 30% of aldosterone is freely available [17], explaining the
moderate mineralocorticoid activity of 11-DOC in vivo. However, supra-
physiological 11-DOC levels can cause inappropriate activation of mi-
neralocorticoid receptors (MR) and promote volume expansion and
hypertension [16]. Moreover, decreased CYP11B1/2 activity results in
elevated concentrations of adrenal androgens due to feedback regula-
tion and increased adrenal steroidogenesis. In contrast, inhibition of
CYP17A1 lowers cortisol and androgen production and, due to feedback
and activation of steroidogenesis, promotes increased levels of 11-DOC,
corticosterone and aldosterone. In both cases, the low cortisol levels
cause an elevation of adrenocorticotropic hormone (ACTH) that further
stimulates the adrenal glands and enhances the production of miner-
alocorticoids.
2.1.1. Itraconazole and posaconazole
A number of recent case reports have described the occurrence of
severe hypokalemia and hypertension together with low renin and al-
dosterone levels secondary to antifungal therapy with the azole anti-
fungals posaconazole and itraconazole [18–26]. Boughton et al. [18]
and Barton et al. [19] reported two cases of posaconazole-induced
hypertension and hypokalemia with markedly elevated serum 11-DOC
and 11-deoxycortisol concentrations that exceeded the upper limit of
the normal range by 10–20 fold. These observations provided evidence
for inhibition of CYP11B1 by posaconazole. Besides, both studies re-
ported increased androstenedione and 17-hydroxyprogesterone levels,
indicating that CYP17A1 was not compromised. The reported high
serum 11-DOC and androgen concentrations differ from those found in
a patient receiving posaconazole that showed normal 11-DOC and an-
drogen levels, along with an increased cortisol/cortisone ratio [22].
However, the moderately elevated 11-deoxycortisol as well as 17-hy-
droxyprogesterone concentrations seemed to account at least for partial
CYP11B1 inhibition. In addition, Wassermann et al. described a case
with clearly elevated 11-deoxycortisol levels and an increased serum
cortisol/cortisone ratio during posaconazole treatment [24], further
supporting inhibition of both CYP11B1 and CYP11B2 by this azole.
These reports did not or only partially assess the patient’s plasma and
urinary steroid profile, allowing only a limited insight into the me-
chanism of azole-induced hypertension and hypokalemia. However, a
recent report on two cases of posaconazole-induced hypertension and
hypokalemia that included detailed steroid metabolite analyses in
blood and urine samples emphasized inter-individual differences in the
mechanism underlying mineralocorticoid-dependent hypertension and
hypokalemia, with predominant inhibition of CYP11B1 and CYP11B2
in one patient and predominant inhibition of 11β-HSD2 in the other
[26].
Importantly, all cited case studies have reported serum drug con-
centrations that exceeded the therapeutic range. In three cases, a low-
ering of the dose resolved the mineralocorticoid symptoms [22–24].
Substitution of posaconazole or itraconazole with voriconazole or flu-
conazole also resolved the mineralocorticoid phenotype [21,22,25,26].
It is accepted knowledge that most azole antifungals are potent
CYP3A4 inhibitors [27,28]. Therefore, care has to be taken when co-
administering drugs that are metabolized by CYP3A4 (e.g. corticoster-
oids). For the same reason, a combined use of calcium channel blockers
and itraconazole should be avoided as this can cause negative inotropic
effects [29]. Moreover, ketoconazole and itraconazole are potent in-
hibitors of the efflux pump P-glycoprotein (P-gp) [30]. Therefore, doses
of substrates of P-gp, such as corticosteroids or cyclosporin A, should be
lowered when they are co-administered with these azoles.
In addition to CYP11B inhibition, certain azole fungicides have been
shown to interfere with the cortisol-metabolizing enzyme 11β-hydro-
xysteroid dehydrogenase type 2 (11β-HSD2) (discussed in section
2.2.2).
2.1.2. Ketoconazole
Ketoconazole, the first orally active azole-type antifungal agent, was
introduced in the early 1980s to treat systemic fungal infections
[31,32]. Soon after its market launch, several studies reported low
serum testosterone levels [33,34], the development of gynecomastia
[35], and glucocorticoid suppression [36] upon long-term ketoconazole
treatment. Inhibition of enzymes involved in adrenal and gonadal
steroid synthesis, particularly CYP11A1, CYP17A1 and CYP11B1, was
found to be responsible for this phenotype [37–39]. Therefore, keto-
conazole has subsequently been used on an off-label basis to treat pa-
tients with endogenous hypercortisolism, i.e. Cushing’s syndrome (CS).
The therapeutic efficacy of long-term ketoconazole treatment of pa-
tients suffering from CS has been confirmed by several studies (re-
viewed by [40,41]). However, most of these studies included only a
small number of patients, with the exception of a retrospective multi-
center study involving 200 patients [42]. This study reported un-
resolved hypertension (50%) and hypokalemia (61.6%) in patients re-
ceiving ketoconazole as pre-surgical treatment (n= 40), and about
60% of patients receiving ketoconazole as primary or secondary treat-
ment (n= 160) showed hypertension and hypokalemia. Generally,
patients showed higher improvement rates for the endpoints ‘clinical
signs’ and ‘diabetes’. Unfortunately, no further results regarding im-
provement of hypertension and hypokalemia were shown, probably
because the associated symptoms are barely distinguishable from the
symptoms of CS itself. Two earlier studies reported sustained
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hypertension with high-dose or long-term ketoconazole treatment in a
minor subset of patients exhibiting increased plasma levels of 11-DOC
and 11-deoxycortisol but markedly decreased cortisol and normal al-
dosterone concentrations [43,44], in line with potent inhibition of
CYP11B1 but weak or moderate inhibition of CYP11B2. In 2013, the
European Medicines Agency (EMA) and the Federal Drug Administra-
tion (FDA) restricted the use of ketoconazole for the treatment of fungal
infections due to concerns of severe hepatotoxicity. This led to a change
in the prescribing guidance in CS [40,45,46]. Nevertheless, the limited
alternative options for the treatment of CS and the proven efficacy of
ketoconazole contributed to its reapproval by the EMA for CS. In order
to overcome the safety issue, levoketoconazole, the 2S,4R-enantiomer
of ketoconazole, is currently under investigation, since it is claimed to
provide higher specificity and thus safety than the racemic compound
(reviewed in [47]).
2.1.3. Metyrapone
Besides ketoconazole, the most commonly used drug for CS therapy
is metyrapone [40,48], an inhibitor of CYP11B1 and, to a lesser extent,
of CYP11B2 and CYP17A1 [49] that was developed for this indication
[50]. Oral administration of a dose of 750mg of metyrapone to CS
patients decreased serum cortisol concentrations within 2 h [51],
whereby patients with reduced hepatic function and thereby decreased
cortisol catabolism can display a delayed response [52]. The potent
cortisol-lowering effect of metyrapone results in attenuation of negative
feedback and thus causes an increase in ACTH, which stimulates ster-
oidogenesis. The concomitant accumulation of androgens and 11-DOC
[50,51,53] may cause adverse effects, such as hirsutism, worsening of
acne, hypertension, hypokalemia and edema. Although the miner-
alocorticoid-dependent effects due to increased 11-DOC concentrations
might be expected to occur frequently, hypertension, hypokalemia and
edema have only rarely been described [51,54]. Metyrapone has in-
itially been used for the differential diagnosis of ACTH-dependent forms
of CS and to assess the functional integrity of the hypothalamo-pitui-
tary-adrenal axis [55,56]. Caution has to be taken when interpreting
results from immunoassays of metyrapone-increased concentrations of
11-deoxycortisol, as this steroid can cross-react with cortisol and
therefore leading to apparently high cortisol levels and to potentially
erroneous clinical decisions [57].
2.1.4. Osilodrostat
Osilodrostat (LCI699) is a novel aldosterone synthase (CYP11B2)
inhibitor developed for the treatment of PA and essential hypertension
[58–60]. However, an earlier proof-of concept study with patients
suffering from PA reported 7- and 14-fold elevated 11-DOC levels after
0.5 mg and 1mg of LCI699, respectively [59]. Moreover, plasma ACTH
levels of these patients increased, whereas potassium concentrations
decreased; but only a mild decrease (4mm Hg) of systolic blood pres-
sure was noted after 4 weeks of treatment. Plasma cortisol levels re-
mained stable, whereas 11-deoxcortisol concentrations increased 4-fold
above baseline. The increased ACTH together with maintained cortisol
indicates CYP11B1 inhibition with a subsequent compensatory increase
of adrenal steroidogenic output, explaining the rise in 11-DOC and 11-
deoxycortisol. Osilodrostat is currently evaluated for its efficacy and
safety in the treatment of CS in a phase III study [61]. In two phase II
studies with CS patients, improved urinary cortisol levels were found,
along with dramatically increased concentrations of 11-DOC and 11-
deoxycortisol as well as mild hypokalemia [62,63]. One of these studies
[62] found no blood pressure decrease, most likely as a result of the
increased 11-DOC levels that may have reversed the blood pressure-
lowering effect of CYP11B2 inhibition. The other study [63] observed a
trend towards decreased blood pressure; however, as antihypertensive
medication was not restricted, a medication bias cannot be excluded.
Further, four phase II studies in patients with different forms of hy-
pertension revealed astonishing results: Lower doses of LCI699 reduced
and higher doses increased blood pressure [60]. The authors
interpreted the latter result by the supra-physiological 11-DOC con-
centrations.
Several CYP11B2 inhibitors are currently assessed in preclinical
studies and two of them entered phase I clinical trials [64,65]. A re-
duction of aldosterone levels in healthy subjects but an elevation of 11-
DOC and 11-deoxycortisol levels was found with both compounds.
Their effect on blood pressure in hypertensive patients will be assessed
in subsequent phase II studies.
2.1.5. Abiraterone, orteronel and VT-464
The biosynthesis of the main androgen precursor dehydroepian-
drosterone (DHEA) from pregnenolone includes only one enzyme,
CYP17A1. In human, it catalyzes the 17α-hydroxylation of both,
pregnenolone and progesterone with equal affinities, whereas the
subsequent 17,20-lyase reaction preferably converts 17α-hydro-
xypregnenolone to DHEA rather than 17α-hydroxyprogesterone to an-
drostenedione (reviewed in [66]). Abiraterone, a synthetic steroidal
compound, significantly reduces androgen levels in castrate-resistant
prostate cancer by equally inhibiting the 17α-hydroxylase and 17,20-
lyase activities of CYP17A1 [67,68]. However, as a consequence of 17α-
hydroxylase inhibition, the production of cortisol is also diminished,
leading to an adaptive rise in ACTH levels, which in turn stimulates
adrenal steroidogenesis and results in the accumulation of 11-DOC,
corticosterone, and aldosterone. Due to the resulting mineralocorticoid
excess, hypertension, hypokalemia and fluid retention are common
adverse effects of abiraterone [69]. To counteract adrenal insufficiency
and mineralocorticoid excess, and thus to overcome the drug-induced
hypertension, patients undergoing abiraterone therapy are co- ad-
ministered prednisone or methylprednisolone.
The combined use of abiraterone and the MR antagonist spir-
onolactone should be avoided because spironolactone is also a partial
agonist of the androgen receptor (AR) that can activate the AR in an
androgen-depleted environment, thereby increasing prostate specific
antigen levels [70,71]. The more specific MR antagonist eplerenone
does not activate the wild-type AR but was found to activate a mutant
form of this receptor that occurs in castrate-resistant prostate cancer
[72]. Thus, if glucocorticoid supplementation is not sufficient to control
mineralocorticoid symptoms, the application of amiloride (± hydro-
chlorothiazide) may be the preferred option [70].
To reduce the adverse mineralocorticoid effects, selective 17,20-
lyase inhibitors represent an interesting option. In this regard, the
nonsteroidal compound orteronel was developed. However, because
overall survival rates were not improved in a clinical phase III study,
further development of this compound was terminated [73]. Another
nonsteroidal 17,20-lyase inhibitor, VT-464, is currently being tested in
phase I/II trials and shows promising results without affecting down-
stream glucocorticoid levels [74,75].
2.1.6. Androgenic anabolic steroids
Androgenic anabolic steroids (AAS) are used by athletes and
bodybuilders to enhance muscle strength and appearance. The in-
creasing recreational application of AAS has become a considerable
issue for public health [76], especially when doses are taken that cause
serum concentrations to increase the therapeutic recommendations up
to 100 fold [77–79]. AAS abuse is associated with dose-dependent
cardiac pathologies, elevated blood pressure and edema (reviewed in
[80–82]). Of note, the mechanisms by which AAS, testosterone itself or
its derivatives contribute to or aggravate hypertension are multi-
factorial and incompletely understood [83].
The testosterone derivative danazol has been used since the 1960′s
for the treatment of endometriosis and hereditary angioedema [84]. In
spite of its efficacy, adverse effects limited its use and even led to
market withdrawal in some countries. Vaginal administration may
provide an improved profile, but its use in endometriosis is still only
indicated if no other therapeutic option is available [85,86]. Never-
theless, recent reports have discussed danazol as a potential treatment
K.R. Beck, et al. Pharmacological Research 154 (2020) 104311
3
in telomere diseases or in autoimmune hemolytic disorders [87,88].
Swelling, edema and weight gain belong to the most common adverse
effects of danazol [89]. An early case study described severe hy-
pertension as an additional adverse effect [90]. Salt and water retention
was suggested as main reason for this effect, presumably caused by
weak mineralocorticoid properties of danazol. However, several other
in vitro and in vivo studies have elucidated the effects of danazol on
adrenal function [91–100] and indicated, though with partly contra-
dictory results, inhibition of adrenal 3β-hydroxysteroid dehydrogenase,
21-hydroxylase, and 11β-hydroxylase [91,92,94–96]. Two of these
studies used rat and guinea-pig as model species, and at least some of
the contradictory results might be explained by species differences.
Nevertheless, the majority of the in vivo studies demonstrated un-
changed serum ACTH levels, a minor trend towards lower cortisol and
increased 11-deoxycortisol and DHEAS levels, but decreased DHEA
concentrations. Considerable cross-reactivity between danazol, its me-
tabolites and androgens (DHEA, testosterone, androstenedione) in
radioimmunoassays does not allow a conclusive evaluation [95]. None
of the studies assessed all components of adrenal steroidogenesis. Thus,
a direct interference of danazol with adrenal steroidogenesis, provoking
an elevation of blood pressure, remains questionable and requires fur-
ther research. Moreover, inhibition of the cortisol-metabolizing enzyme
11β-HSD2 by danazol has also been proposed (discussed in section 2.2)
[101].
Whether other AAS interfere with adrenal steroidogenesis and are
able to promote mineralocorticoid-driven hypertension remains to be
elucidated. Interestingly, nandrolone, an AAS used for the treatment of
osteoporosis in postmenopausal women is associated with hypertension
[102], and was found to decrease corticosterone concentrations as well
as adrenal Cyp11b1 mRNA expression in rats [103].
2.2. Inhibition of peripheral steroid metabolizing enzymes
Aldosterone and cortisol exhibit similar affinities for the MR, but
normal circulating cortisol concentrations exceed those of aldosterone
by 100-1000-fold [104,105]. In order to render specificity for aldos-
terone to the MR, the enzyme 11β-HSD2 inactivates cortisol to corti-
sone in mineralocorticoid target tissues, such as the renal cortical col-
lecting duct, the distal tubules or the distal colon [106]. Patients
suffering from a loss-of-function mutation in this enzyme display severe
and early hypertension, hypokalemia, suppressed renin and low al-
dosterone levels [107–110]. This so-called apparent mineralocorticoid
excess can be inherited or de novo.
However, the metabolic inactivation of cortisol might not be suffi-
cient to protect the MR from activation by cortisol. Observations from
enzyme activity measurements showed that 11β-HSD2 converts about
90% of supplied cortisol, suggesting that cortisol is still present at least
at a 10-fold excess over aldosterone, likely occupying the majority of
MR (own observations). Moreover, evidence from animal experiments
indicated that in kidney and colon 11β-HSD2 is insufficient to exclude
the physiologically active glucocorticoid from epithelial MR [111],
suggesting that active glucocorticoids are bound to MR but the receptor
exists in an inactive state.
To allow aldosterone to tune the activity of the MR, Funder [112]
proposed that the high local levels of NADH, generated from NAD+ by
the 11β-HSD2-catalyzed oxidation of cortisol to cortisone in close
proximity to the MR [113], allosterically keep cortisol-MR complexes in
an inactive state. In support of that, it has been shown that the cor-
epressor carboxyl-terminal binding protein serves as a metabolic sensor
[114]. As a consequence of this regulation, inhibition of 11β-HSD2 and
redox changes occurring under conditions of oxidative stress or tissue
damage can decrease NADH levels and result in cortisol-induced MR
activation.
2.2.1. Licorice and carbenoxolone
The most prominent example of acquired apparent
mineralocorticoid excess is the licorice-dependent inhibition of 11β-
HSD2 [115]. Licorice and its active component glycyrrhetinic acid are
widely used as flavoring additives in dietary products, such as drinks
and candies, or in cigarettes and chewing tobacco [116]. Moreover,
licorice root has a long history as herbal remedy for a broad range of
therapeutic applications and is still used, particularly in traditional
Asian medicine, as yokukansan [117–119] or mumijo [120]. The ex-
posure to licorice is particularly critical during pregnancy. The fetus is
protected from the 5-10-fold increased maternal cortisol levels during
pregnancy by highly expressed placental 11β-HSD2 [121–124]. Ob-
servational studies implicated shorter gestation times, poorer cognitive
function and behavioral disturbances associated with an increased ac-
tivity of the HPA axis after maternal consumption of large amounts of
licorice [125–127]. Furthermore, although the underlying etiology is
incompletely understood, reduced 11β-HSD2 activity has been reported
to be involved in preeclampsia [128,129].
The structure of glycyrrhetinic acid served as a basis for the
synthesis of carbenoxolone as a therapeutic agent for gastric and duo-
denal ulcers. Although clinical studies of carbenoxolone were successful
in treating gastric ulcers, its mineralocorticoid-type adverse effects due
to 11β-HSD2 inhibition and the discovery of H. pylori as major cause of
peptic ulcers, along with specific antibiotic therapy, have limited its use
[116,130].
2.2.2. Itraconazole and posaconazole (see also 2.1.1)
Despite its important physiological role, 11β-HSD2 is not included
in current preclinical off-target screening approaches. Thus, a recent
study evaluated possible inhibitory effects of approved drugs on 11β-
HSD2 [131] and identified itraconazole, its active metabolite hydroxy-
itraconazole and posaconazole as potent 11β-HSD2-inhibitiors in vitro.
Interestingly, important species-specific differences between human
and rodent 11β-HSD2 were found, potentially leading to biased results.
As discussed in section 2.1.1, these compounds might inhibit CYP11B1
and CYP11B2 but also 11β-HSD2 activity in vivo. Two case studies re-
ported occurrence of hypertension and hypokalemia, as well as lowered
renin and aldosterone levels following itraconazole treatment [20,21].
In both studies, patients had serum itraconazole and hydroxy-itraco-
nazole concentrations above the therapeutic range, whereas cortisol,
ACTH and 11-DOC levels were unaltered. These observations resemble
the syndrome of apparent mineralocorticoid excess. The patient de-
scribed by Hoffmann et al. [21] showed slightly elevated 11-deox-
ycortisol levels, indicating a partial inhibition of CYP11B1. Based on
the available reports describing pseudohyperaldosteronism secondary
to itraconazole or posaconazole treatment, it is difficult to fully assign
the relative contributions of CYP11B and 11β-HSD2 inhibition. While
itraconazole appears to preferably inhibit 11β-HSD2, leading to cor-
tisol-dependent MR activation, posaconazole shows a dual mechanism
with more pronounced effects towards CYP11B1, resulting in 11-DOC-
mediated MR activation.
2.3. Mineralocorticoid receptor activation
2.3.1. Corticosteroids
Direct stimulation of the MR as is the case for aldosterone, results in
increased renal sodium retention and potassium excretion, causing
hypokalemia and hypernatremia, volume expansion and increased
blood pressure. The synthetic mineralocorticoid fludrocortisone (also
known as 9α-fluorocortisol) is used, usually in combination with a GR
agonist, as replacement therapy in adrenal insufficiency, particularly in
patients suffering from Addison’s disease [132]. The potency of flu-
drocortisone to activate MR is 200–400 times greater than that of
cortisol, although both steroids exhibit similar receptor biding affinities
[133–136]. Moreover, because of its fluoro substituent, fludrocortisone
was hypothesized to be protected from metabolism by 11β-HSD2 [137];
however, whether the 11-keto form is indeed produced and is active at
the corticosteroid receptors, as is the case for the fluorinated
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glucocorticoid dexamethasone [138], remains to be determined.
As mentioned, cortisol possesses considerable potency to activate
MR and can therefore disrupt the electrolyte balance, leading to edema
formation and hypertension. Studies addressing the role of the MR in
cortisol-induced hypertension showed diminished mineralocorticoid
effects upon co-administration of spironolactone, but no effect on blood
pressure, suggesting that the mineralocorticoid effects are not solely
responsible for cortisol-induced hypertension [139,140]. Increasing
evidence even speaks against a major role of the MR in glucocorticoid-
dependent hypertension but implicates other targets, such as altered
nitric oxide synthase activity or increased expression of AT1 receptors
(reviewed by [141–143]). These observations are further supported by
the fact that dexamethasone, which has negligible MR activity [138],
can also cause hypertension. Thus, antihypertensive treatment of glu-
cocorticoid-induced hypertension with angiotensin converting enzyme
(ACE) inhibitors or angiotensin receptor antagonists might represent
the best option.
2.3.2. Mifepristone
Mifepristone is an antagonist at progesterone receptors and thus can
induce abortion in first-trimester pregnancies. However, mifepristone is
also a potent GR antagonist and has been approved in 2012 by the US
FDA for the treatment of hyperglycemia associated with CS [144].
Paradoxically, prolonged administration of this GR antagonist causes
HPA axis activation and leads to increased ACTH and cortisol levels
[145,146]. As a result of the disrupted negative HPA feedback, the
elevated cortisol (and corticosterone) concentrations can activate MRs
and promote hypokalemia, hypertension and edema [147–150].
2.4. Renin–angiotensin–aldosterone system
Indirect activation of the renin–angiotensin–aldosterone system
(RAAS) represents a mechanism by which several drugs, such as non-
steroidal anti-inflammatory drugs (NSAIDs), estrogens, cyclosporine A
and erythropoietin, and also alcohol, can promote hypertension, often
in combination with other mechanisms (reviewed by [7,10,151,152]).
A detailed discussion of the numerous mechanisms that activate the
RAAS exceeds the scope of the current review that focuses on the most
frequently used medications.
2.4.1. NSAIDs
Both selective cyclooxygenase type 2 (COX-2) and nonselective
cyclooxygenase inhibitors have been reported to induce blood pressure
elevation, particularly in patients with pre-existing hypertension
[153–156]. The prostaglandins PGE2 and PGI2 are involved in the
regulation of renal vasodilatation and renin synthesis, thereby con-
trolling renal perfusion and salt homeostasis. By inhibiting the COX-
mediated generation of prostaglandins, NSAIDs can impair renal func-
tion and lead to sodium retention, hyperkalemia and hyporeninemic
hypoaldosteronism [155,157]. The nonselective NSAIDs indomethacin,
naproxen and piroxicam have been associated with the highest risk to
promote hypertension [155]. Rofecoxib, which has been withdrawn
from the market, was shown among COX-2 inhibitors in earlier studies
more likely to induce hypertension than celecoxib [158,159].
The blood pressure increasing effect of the different NSAIDs de-
pends on their dose, treatment duration, patient’s age, co-morbidities,
co-medications, and dietary salt intake. Thus, particularly in high risk
patients, dose and duration of therapy with NSAIDs should be reduced
to a minimum and blood pressure should be monitored.
In addition to their own blood pressure increasing effect, NSAIDs
may blunt the effectiveness of antihypertensive agents that reduce the
activity of the RAAS. This includes inhibitors of renin and ACE, an-
giotensin receptor antagonists, diuretics and β-blockers. In contrast,
calcium channel blockers maintain their antihypertensive properties
with concurrent NSAID administration and may therefore be the pre-
ferred antihypertensive therapy in such cases [153,160–163].
2.4.2. Oral contraceptives
A moderately increased risk of hypertension in women using oral
contraceptives was reported in a prospective cohort study lasting 4
years [164]. The increased risk diminished rapidly with cessation of
contraceptives. This risk was associated with high doses of proestrogens
(≥50 μg of daily ethinyl estradiol) and less with lower doses (≤30 μg of
daily ethinyl estradiol; reviewed in [165]). Progesterone-only agents
(“mini-pills”) were devoid of a blood pressure rising activity [166].
Thus, these drugs are the favorable contraceptive option for hyperten-
sive women. Drospirenone, a progestogen structurally related to spir-
onolactone possessing about eight times the antimineralocorticoid ac-
tivity of the latter [167], was shown to lower blood pressure [168,169].
However, increasing evidence suggests a higher risk of drospirenone-
containing contraceptives causing deep vein thrombosis and pulmonary
embolism [170–174]. In a recent small study, it was shown that vaginal
rings releasing daily 15 μg of ethinyl estradiol and 120 μg of etono-
gestrel slightly increased 24 h diastolic (2.75 ± 5.13mm Hg) and
mean (2.69 ± 5.35mm Hg) 24 h ambulatory blood pressure [175].
Estrogens participate in blood pressure elevation by a number of
mechanisms that have not been fully elucidated. It was suggested that
estrogens can modulate the RAAS-system by increasing expression le-
vels of angiotensinogen and of AT1 receptors [165,176–178].
3. Catecholamines
The three catecholaminergic neurotransmitters dopamine, nora-
drenaline (norepinephrine) and adrenaline (epinephrine) are derived
from the amino acid tyrosine. Their agonistic (“sympathomimetic”)
activity on adrenergic receptors affects many metabolic and cardio-
vascular processes, including blood pressure, myocardial contractility
and heart rate. Catecholamine-secreting tumors, so-called pheochro-
mocytoma (including adrenal and extra-adrenal paraganglioma), be-
long to the less prevalent causes of secondary (paroxysmal) hyperten-
sion. For diagnosis, it is crucial to consider drugs that share the same
mechanism and may lead to an increase of catecholamines and their
metabolites, the metanephrines, thereby causing symptoms of pheo-
chromocytoma, including endocrine hypertension [2,179]. Moreover, it
is important to consider medications that can precipitate a hypertensive
crisis in patients with pheochromocytoma. In particular, the following
drug classes should be taken into account [2,6]: β-adrenergic receptor
blockers (nonselective ones such as propranolol and timolol or high
doses of β1-blockers such as sotalol, nadolol and labetalol), dopamine
D2 receptor antagonists (metoclopramide, sulpiride, amisulpride, tia-
pride, chlorpromazine, prochlorperazine, droperidol), sympathomi-
metics (discussed in the following section), noradrenaline reuptake
inhibitors (including tricyclic antidepressants (TCA)), monoamine oxi-
dase (MAO) inhibitors, opioid analgesics (morphine, pethidine, tra-
madol), corticosteroids, ACTH, glucagon or neuromuscular blocking
agents (succinylcholine, tubocurarine and atracurium).
3.1. Sympathomimetic amines
Noradrenaline increases vasoconstriction and therefore blood pres-
sure via α-adrenergic receptors. It is used for reanimation in emergency
medicine, acute hypotensive conditions or after cardiac arrest [180].
Adrenaline that activates α- and β-adrenergic receptors is used for
emergency cases of severe anaphylactic reactions and for resuscitation.
3.1.1. Decongestants
Nasal and oral decongestants like xylometazoline, oxymetazoline,
phenylephrine and pseudoephedrine are among the most frequently
used non-prescription drugs. They cause vasoconstriction by stimu-
lating α1-adrenergic receptors. Their oral formulations can lead to
blood pressure elevation as has been described for oral phenylpropa-
nolamine [181] and pseudoephedrine [182] although no effect on
blood pressure of patients with well-controlled hypertension and
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standard pseudoephedrine doses was found [183,184]. Thus, short-
term oral decongestant treatment with α1-adrenergic agonists can be
regarded as safe.
Phenylephrine is often co-administered with acetaminophen, which
has been reported to increase the bioavailability of phenylephrine.
Doses of 650–1000mg of acetaminophen nearly quadrupled the Cmax
and doubled the AUC of 10mg phenylephrine, and this was not asso-
ciated with changes in blood pressure in healthy volunteers [185–187].
Nevertheless, the combination treatment of acetaminophen with phe-
nylephrine has the potential to increase blood pressure compared to
phenylephrine alone in patients with underlying hypertension [187].
Furthermore, combination therapies of sympathomimetic amines with
MAO inhibitors, TCA or ergot alkaloids are contraindicated, since these
drugs can amplify sympathomimetic effects.
3.1.2. Anti-obesity drugs
Obesity is associated with many comorbidities including hyperten-
sion [188]. Early drugs were often derivatives of amphetamine that
inhibit reuptake of catecholamines and suppress appetite; many had
considerable cardiovascular safety issues, leading to their market
withdrawal [189]. As a result, the EMA revised the safety requirements
[190] and released a new guideline for medical products used in weight
control in 2016 [191].
An example is sibutramine. It inhibits noradrenaline and serotonin
reuptake and was initially developed as an antidepressant and later
established as an anorexiant [192]. The blood pressure reduction at-
tributable to the patient’s weight loss was found to be attenuated or
even slightly increased due to the sympathomimetic effect of sibu-
tramine; this was considered a therapeutic dilemma early after its
market launch [193]. Since additional adverse cardiovascular events
were reported in sibutramine-treated patients, a long-term large-scale
prospective trial was carried out to evaluate its efficacy/safety ratio
(reviewed in [194]). The benefits of the drug as a weight-reducing
agent did not outweigh its cardiovascular risks, and therefore, the EMA
and FDA suspended its market authorization [195,196].
3.2. Psychostimulants
3.2.1. Methylphenidate
Over the past 20–30 years, concerns have been raised regarding the
cardiac safety of psychostimulants used for the treatment of children
and adolescents with Attention Deficit/Hyperactivity Disorder (ADHD)
[197]. Systematic reviews and meta-analyses assessing cardiovascular
outcomes of methylphenidate, which inhibits noradrenaline and do-
pamine reuptake, reported a small but significant increase of systolic
blood pressure in children/adolescents and adults with ADHD
[198,199]. This led to an assessment of the benefit/risk ratio of me-
thylphenidate-containing medicines by the regulatory bodies
[200,201]. The EMA’s Committee for Medicinal Products for Human
Use and the American Heart Association concluded that the benefits of
methylphenidate continue to outweigh its risks and therefore reported
no urgent need to restrict its use [197,200]. However, family history
analyses, cardiovascular pre-treatment and regular blood pressure and
heart rate monitoring were recommended. Data on long-term cardio-
vascular effects of methylphenidate are not available; to continue me-
thylphenidate therapy, a one-year drug-free program is recommended
before methylphenidate treatment is resumed [200]. The α2-adrenor-
eceptor agonist guanfacine can be used as an antidote for methylphe-
nidate-induced hypertension.
3.2.2. Lisdexamphetamine
Due to the considerable misuse potential of d-amphetamine, lis-
dexamphetamine, a prodrug consisting of covalently linked d-amphe-
tamine to L-lysine, was approved for the treatment of ADHD (reviewed
in [202,203]). After oral administration, lisdexamphetamine is hydro-
lyzed to its active component d-amphetamine [204]. Although
amphetamine is not a catecholamine, it acts as an “indirect sym-
pathomimetic amine” by inhibiting noradrenaline and dopamine re-
uptake. As for the parent drug, a dose-related blood pressure increase
has been reported for lisdexamphetamine [205]. The conversion of this
prodrug was thought to occur gradually, leading to low d-amphetamine
plasma concentrations, prolonged action, and therefore a safer profile
[203,205]. Such a prolonged pharmacokinetic profile was linked with
delayed dopamine release, decreased euphoric effects and a possibly
lower risk of abuse [202,205].
However, no industry-independent studies were available and nei-
ther were comparative pharmacokinetic data of d-amphetamine and
lisdexamphetamine. A recent study addressing this gap found a short
lag time of amphetamine plasma concentrations after administering
lisdexamphetamine but no difference in Cmax and AUC between the two
treatments [206]. Moreover, both drugs after a single dose caused si-
milar peak increases in systolic (from 120 to 160mm Hg) and diastolic
blood pressure (from 75 to 90mm Hg). Additionally, ACTH, gluco-
corticoid, androgen and 11-DOC levels were similarly enhanced but no
changes of aldosterone concentrations with lisdexamphetamine and d-
amphetamine treatment were noted [207]. Single and high-dose
treatments are the major limitations of this study. Whether activation of
the HPA axis may further enhance blood pressure or whether repeated
administration of lisdexamphetamine (or d-amphetamine) may lead to
tolerance, remain to be addressed. Interestingly, among the adverse
effects listed in the prescribing information, children and adolescents
are reported to occasionally (≥1:1000 to< 1:100) develop increased
blood pressure, whereas adults seem to be affected more frequently
(≥1:100 to< 1:10) [208].
3.2.3. Atomoxetine
Atomoxetine is a selective noradrenaline uptake inhibitor used for
the treatment of ADHD. Hypertension was reported as a highly variable
adverse effect already during its market authorization studies [209].
Thus, it is recommended to assess the patient’s blood pressure prior to
and during therapy.
3.3. Antidepressants
3.3.1. Serotonin-noradrenaline reuptake inhibitors (SNRIs)
SNRIs inhibit the neuronal reuptake of noradrenaline and serotonin.
Venlafaxine is approximately 30 times more selective for serotonin than
noradrenaline reuptake, whereas duloxetine is ˜10 times more selective
[210]. In contrast to selective serotonin reuptake inhibitors (SSRIs),
which display a constant adverse effect profile throughout their dose
range, adverse effects of SNRIs increase with increasing dosage
[211,212]. In this regard, the adverse effects due to noradrenaline re-
uptake inhibition, such as tachycardia, tremor and mild but sustained
hypertension occur at higher doses of both duloxetine and venlafaxine
[211]. The latter and its major active metabolite desvenlafaxine have
been reported to lead to a mildly raised blood pressure with increasing
doses [209,213–216]. The same is the case for duloxetine, although no
consistent dose-relationship has been demonstrated [217]. Therefore,
patients with preexisting hypertension should be carefully monitored or
administered a SSRI, if possible.
3.3.2. Bupropion
Bupropion, a noradrenaline-dopamine reuptake inhibitor, is ap-
proved for the treatment of major depressive disorders and for smoking
cessation, but also to treat ADHD on an off-label basis. In spite of re-
ports of spontaneous hypertension and package label warnings for use
in hypertensive patients, data regarding blood pressure effects are
conflicting [10,209,218].
3.3.3. MAO inhibitors
MAO blockers inhibit the oxidative inactivation of monoamines,
such as serotonin, noradrenaline and dopamine, causing their levels to
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increase. There are two isoforms, MAO-A and MAO-B. Selective MAO-A
inhibitors, such as moclobemide, are used to treat depression and an-
xiety, whereas MAO-B inhibitors, such as selegilin and rasagilin, are
used in Parkinson’s disease due to their relative specificity to inhibit
dopamine oxidation. The pharmacodynamic interaction of MAO in-
hibitors with the foodborne biogenic amine tyramine is considered as a
rare but serious interaction, potentially leading to a hypertensive crisis
[219]. This interaction particularly affects non-selective and irrever-
sible MAO inhibitors (e.g. tranylcypromine). Adaptations of food pro-
duction technology led to lower levels of tyramine and only patients
receiving non-selective or irreversible MAO inhibitors need to pay at-
tention on their diet. A common misconception is that MAO inhibitors
increase the blood pressure and should be avoided in patients with
hypertension. Indeed, MAO inhibitors were applied in the early 1960s
to treat hypertension [220,221]. However, MAO inhibitors should not
be prescribed for patients with pheochromocytoma or ADHD therapy
with methylphenidate, lisdexamphetamine or amoxetine due to the risk
of a hypertensive crisis. A recent study of three pheochromocytoma
patients, reported symptoms of severe depression and anxiety disorders
[222]. After surgical resection, these disorders disappeared, empha-
sizing to include pheochromocytoma in the differential diagnosis of
long-term panic disorders refractory to medication.
3.3.4. Tricyclic antidepressants (TCA)
The introduction of SSRIs reduced the use of TCAs, which inhibit
noradrenaline and serotonin reuptake with variable selectivity de-
pending on their structure. TCAs are sometimes suspected to lead to
hypertension, although therapeutic doses are correlated with postural
hypotension and tachycardia [223].
This “hypertensinogenic hypothesis” is based on an early report of
patients with panic disorders or major depression undergoing TCA
therapy [224] and found the development of hypertension in 6 out of
114 patients - all suffering from panic disorders but none with major
depression alone - suggesting a probable reporting bias [209,225].
However, TCA-induced hypertension reactions should be considered in
patients with pheochromocytoma or in co-medicated patients receiving
sympathomimetics or MAO inhibitors [226]. Furthermore, evaluation
of risk of hyper- or hypotension associated with psychiatric medications
needs to differentiate between sedative (amitriptyline, doxepin) and
non-sedative (desipramine) TCAs, since sedative TCAs show an even
stronger association with (orthostatic) hypotension [209].
3.4. Mirabegron
Mirabegron is the first registered β3-adrenoreceptor agonist used to
treat overactive bladder syndrome. β3-adrenergic receptors are ex-
pressed in the urinary bladder and mediate detrusor muscle relaxation
(reviewed in [227]). In phase III trials, hypertension was the most
common adverse effect of mirabegron [228]. Off-target stimulation of
β1-adrenoreceptors at high mirabegron doses are the likely causes of
these cardiovascular effects, because the mirabegron-induced increase
in blood pressure and heart rate was attenuated by the nonselective β1/
2-adrenoreceptor antagonist propranolol and the selective β1-adrenor-
eceptor antagonist bisoprolol [229].
4. General diagnostic and therapeutic strategies
Suspicion of secondary hypertension should be raised if a patient
shows one of the following characteristics [230]: Acute worsening of
hypertension in previously normotensive or chronically stable patients,
treatment-resistant hypertension, young hypertensive patients, or
clinico-biochemical features suggesting an endocrine cause. In order to
distinguish a drug-induced from an endogenous cause, a detailed as-
sessment of the patient’s medication, the use of over-the-counter drugs
or herbal supplements, and the dietary behavior should be conducted.
In order to avoid artifacts of analytical results, precautions are
necessary. This is particularly important for the diagnosis of pheo-
chromocytoma and paraganglioma [231]. When a substance is sus-
pected to interfere with the hormonal system or directly with the bio-
chemical test, the test should be repeated after elimination of
potentially interfering agents and additional diagnostic tests should be
performed.
The majority of the blood pressure changes induced by the drugs
described above are comparatively minor and many of them are tran-
sient. However, the degree of the hypertensive effect may vary between
subgroups of the population, with elderly or patients already suffering
from hypertension or renal failure at a higher risk [8]. Such patients
should be advised to measure their blood pressure at home, on occasion
under surveillance by healthcare providers [232]. A recent review
suggested home blood pressure monitoring as a prognostic indicator
that is better than office blood pressure measurement [233].
Despite the different mechanisms by which drugs can elevate blood
pressure, a few general considerations should be addressed:
• Polymedicated patients and their diets, such as consumption of
grapefruit juice, should be assessed to rule out potential drug-drug
and drug-food interactions, provoking adverse effects.
• It should be routinely reassessed whether continuation of treatment
is still required. Should this be the case, substitution, dose de-es-
calation or limitation of drug exposure should be considered.
• Depending on the underlying mechanism, an alternative anti-
hypertensive therapy should be introduced [10].
• For first-line treatment of mineralocorticoid excess, a MR antago-
nist, i.e. spironolactone or eplerenone (potentially finrenone in the
near future), together with potassium supplementation should be
the treatment of choice. Exceptions: a) In prostate cancer patients
receiving abiraterone, the partial agonist effect of spironolactone
might promote tumor growth. b) As eplerenone is metabolized by
CYP3A4, it should not be used in combination with CYP3A4 in-
hibitors, such as azole fungicides.
• To address volume retention and edema, potassium-sparing diure-
tics might be indicated, particularly in situations of hypokalemia.
• The most appropriate method to circumvent adverse effects is often
to lower the drug exposure. This is particularly the case for non-
prescription drugs, including most NSAIDs, decongestants, herbal
remedies or licorice-containing products. Thus, to avoid un-
necessary long drug administration, patients should be informed
about the optimal dosage and duration of treatment.
• ACE inhibitors and AT1 receptor antagonists are associated with
hyperkalemia, especially in patients with chronic renal insufficiency
[234,235]. To avoid dose de-escalation or even therapy dis-
continuation and thereby compromising blood pressure control,
administration of a recently authorized potassium lowering agent,
sodium zirconium cyclosilicate, might allow treatment continuation
[236].
In conclusion, drugs associated with blood pressure elevation should
be critically considered as treatment option, except in patients suffering
from uncontrolled hypertension. Routinely monitoring blood pressure
is recommended for early identification of hypertension followed by an
appropriate therapeutic strategy.
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